

# Tables

---

1.1	Classification of 153 Canadian studies from 2001 to 2006	15
1.2	Costs and effects for alternative gallstone treatments	18
1.3	Cost and effect per patient for worksite care and regular care	19
1.4	Detection rates for successive stool guaiac tests	22
1.5	Bednet usage in Kenya in the Millennium Village and in the MV region	25
1.6	Evaluation of neo-natal intensive care treatment	26
2.1	Short run production function for lengths of stay	35
2.2	Short run cost curves for lengths of stay	35
2.3	Long run production function for lengths of stay	36
2.4	Discount factors for alternative time horizons and interest rates	38
2.5	Avoidable costs in SEK of liver cirrhosis for women compared to base year, ten years	39
2.6	Reference requirements for five treatments (per 100 bed-days)	45
2.7	Costs and cost-effectiveness ( <i>C/E</i> ) for three live kidney donor transplant treatments	46
2.8	Inflation-controlled hospital costs for total knee arthroplasty	48
2.9	Total costs and cost profiles of 17 prevention interventions targeting CSWs in Tamil Nadu and Andhra Pradesh in India in 2002–03	51
2.10	Lifetime costs of HIV	54
2.11	Costs of different treatments before and after treatment	56
2.12	Costs of liver cirrhosis for women compared to base year, 24 years	58
3.1	Percentage of cases where RCC-estimated costs are within 10 percent of RVU-estimated costs	70
3.2	DATCAP costs from 110 substance abuse treatment programs	72
3.3	Estimates of economies of scope for Danish hospitals	74
3.4	DRGs that give different profitability outcomes using RVUs and RCCs	76
3.5	Resource based relative values and Medicare charges	78
3.6	Estimates of the share of the physician's bill that counts as costs	81
3.7	DATCAP costs for 302 clients and 440 client episodes	82
3.8	Human resource cost per chest X-ray films	84
3.9	Hypothetical translation of a patient's bill: charges to costs	85
3.10	Hypothetical use of cost centers	85
4.1	Consequences of increased taxes in consumer surplus loss to drinkers and lives saved	102
4.2	Literature estimates of costs and benefits on a comparable basis	105
4.3	Comparison of optimal and actual policies for schistosomiasis	109
4.4	Effect of education of household members on health care outcomes (change in probabilities)	111

4.5	Sensitivity analysis for JE vaccination program in Thailand	112
5.1	Estimates of the marginal cost of funds for the US federal government ( $MCF_p$ )	125
5.2	Estimates of the marginal cost of funds for US state governments ( $MCF_s$ )	126
5.3	Estimates of the marginal cost of funds for 38 African countries	128
5.4	Estimates of the marginal cost of funds using the ratio of average to median household income	130
5.5	Net benefits of a permanent \$1 increase in social security (1985–2060)	134
5.6	Tax rates and MCFs under different scenarios	137
5.7	The data on prices, quantities and costs for non-federal general hospitals (1990)	138
5.8	Net benefits of privatization of non-federal general hospitals in the US	139
5.9	Weighted costs of systems of psychiatric care in Massachusetts	140
5.10	Evaluation of case management programs	142
5.11	The relation between the excess burden and the level of the tax rate	144
6.1	Hypothetical example of the cost-effectiveness paradigm	152
6.2	Hypothetical example of the cost-effectiveness paradigm with competing choices	153
6.3	Cost and effect per patient for worksite care and regular care	154
6.4	Inclusion and exclusion criteria	167
6.5	Optimal spending and the $C/E$ ratio: men, income = \$18 000	172
6.6	Federal evaluation of state psychiatric hospital care	173
6.7	Determinants of decisions concerning alcohol treatment effectiveness	175
6.8	Effects and costs of screening for cervical cancer using the Pap smear	176
6.9	Participant willingness to pay for web-based versus face-to face course delivery modes	177
7.1	Programs with varying timing of costs and benefits	185
7.2	Programs with a delayed timing of costs and effects	187
7.3	Programs with costs that vary by individuals	189
7.4	Confidence intervals for a typical cost-effectiveness calculation using three alternative methods	194
7.5	Using the net-benefit regression results to create cost-effectiveness acceptability curves for the Skilled Care Initiative, Burkina Faso	197
7.6	Wage equation estimates	200
7.7	Estimates of social discount rates for the period 1965–89	202
7.8	Effect of selected variables on calorie consumption	206
7.9	Estimates and 95 percent lower and upper confidence limits for $\bar{E}/\bar{C}$ in the SRTI trial	208
7.10	Confidence intervals for incremental cost-effectiveness ratios, ICD vs EP	209
8.1	Comparative cost–utility results for selected programs	219
8.2	NICE decisions ranked by incremental cost-effectiveness ratio	222
8.3	Calculations of QWB with and without treatment	225
8.4	Top 10 priorities of the Oregon HSC initially and subsequently	227
8.5	Measures of economic evaluation of neonatal intensive care by birth weight	230
8.6	Some extracts of cost for QALYs for competing treatments	232

8.7	NICE decisions ranked by ICER with their associated probability of rejection	236
8.8	Balance sheet of expected effect of demonstration program on number of people covered, services covered and financial costs	238
8.9	Cost-effectiveness ratio estimates of THA and other procedures	242
9.1	Utility values using TTO for patients versus general public by duration	248
9.2	Mean time trade-off and visual analogue scores	250
9.3	Intra-class correlation using time trade-off	251
9.4	The Rosser and Kind index of health status	254
9.5	Valuation of EuroQol health states	261
9.6	Annual transition probabilities for monotherapy	264
9.7	Calculation of life expectancy over 20 cycles for monotherapy for the case study Markov model	265
9.8	Selected results from comparative valuation studies	267
9.9	Mean SG, TTO and RS quality weights for health state E	268
9.10	The seven health profiles included in the experiment	269
9.11	Implied rankings of the seven health profiles for different quality weights	269
9.12	Mean Spearman rank correlation coefficients between the direct rankings and the predicted rankings of RS, TTO and SG	270
9.13	Results for visual function and utility values according to visual acuity	271
9.14	Patients willing to trade time for improved vision (TTO method) and risk immediate death for improved vision (SG method)	272
9.15	Ratings of standardized health states	273
9.16	HUI Mark 2 classification scheme	275
9.17	Change in health state utility after hearing aid fitting and ICER	276
9.18	Coefficient estimates and significance levels of the determinants of HIV/AIDS utilities	278
10.1	Revised disability classes for the Global Burden Disease Study based on the results of the PTO protocol used at the Geneva meeting on disability weights	287
10.2	DALY losses by age at death in Uganda	288
10.3	Comparison of DALYs versus deaths in demographically developing countries by categories of disease	288
10.4	Global disability adjusted life years 1990 to 2010	289
10.5	Life expectancies at birth and after intervention (remaining years)	289
10.6	Utilities for health states with knee condition	293
10.7	The ICECAP-O instrument, attributes and values	298
10.8	The number of lives, life years and QALYs saved among 50-year-olds and 70-year-olds equivalent to saving one life, life year and QALY among 30-year-olds	302
10.9	Incremental cost-effectiveness analysis for sleeping sickness in Uganda	303
10.10	Apparent impact of HIV on mortality: DALYs as compared with HeaLYs, 1990	305
10.11	Comparison of restrained and non-restrained clients	306
10.12	Correlations between ICECAP-O, well-being indices and EuroQoL	308

11.1	The value of a quality adjusted life year (1997 dollars) by study type	323
11.2	WTP per QALY for each health state	324
11.3	WTP per QALY in six countries	325
11.4	Costs and benefits of alternative mental health programs	326
11.5	Age-group specific VSLs	331
11.6	Comparison of the VSLs using the cross-sections with that of the cohort analysis	331
11.7	Costs and benefits of the 55 mph speed limit decision using different numeraires	335
11.8	Summary of Clear Skies initiative benefits based on EPA VSLs versus VSLs estimated by Aldy and Viscusi	337
12.1	Estimated value of waiting list time	354
12.2	Monetary valuations of NHS nursing home care and hospital care for respondents with a preference for NHS nursing home care	364
12.3	Conjoint analysis results for the choice of medication versus surgery for the management of miscarriage	366
12.4	The costs and benefits of mobile screening in NSW	369
13.1	Price elasticities for health in Peru by income quintile	381
13.2	Weighted net benefits of case management programs with alternative sets of distribution weights	391
13.3	Number responding and stated willingness to pay as percentage of family income	392
13.4	Equivalence numbers in questionnaires without and with explicit arguments	393
13.5	Numbers weights for severity of illness corresponding to PTO estimates	394
13.6	Aggregate results: percentage change in total demand accounted for by each income quintile and consumers' welfare loss as a percentage of income by income quintile	395
13.7	Disaggregated results for quantity reductions ( $D_i / D$ ) by quintile	396
13.8	Disaggregated results for benefit losses as a percentage of income ( $B_i / Y_i$ ) by quintile	397
13.9	Disaggregated costs and benefits of raising user fees in Peru by quintile	402
13.10	The weight for each of the three social objectives behind public hospital construction decisions in Turkey	403
14.1	HIV/AIDS by region, December 2012	412
14.2	Costs of MC interventions relative to treating infections not averted due to MC	417
14.3	Cost–benefit outcomes for VCT options	432
14.4	Net benefits per person of ARVs on depressed and non-depressed groups by era	437
14.5	WTP for an HIV/AIDS vaccine according to income	439